How GLP-1 Medications (Semaglutide) Actually Work for Weight Loss

Medically reviewed by Dr. Dan Xu, M.D., CCFP — CPSO Licensed Physician and Founder & Medical Director of ID Cosmetic Clinic, Markham. Last updated June 2026.

Over the past few years, a class of drugs called GLP-1 receptor agonists has reshaped weight-loss medicine worldwide. Ozempic has become a household name; Mounjaro wait-lists run for months. Patients arrive at our Markham clinic asking the same questions: how do these medications actually work, why are the results stronger than anything before them, and is this a good idea for me? This deep-dive explains the science in plain language so you can make a genuinely informed decision. It is general information, not medical advice — your own plan should always come from a one-on-one assessment.

What is GLP-1? Your body’s natural “brake” on eating

GLP-1 stands for glucagon-like peptide-1. It is not something a drug company invented — it is a natural hormone your gut releases every day. After you eat, specialized L-cells in your intestine secrete GLP-1 into the bloodstream, sending a clear signal: you’ve had enough, you can stop now. At the same time it tells the pancreas to release insulin, tells the brain to register fullness, and slows the rate at which the stomach pushes food into the intestine. It is, in effect, a precise “eating brake.”

The catch is that natural GLP-1 is destroyed almost instantly — its half-life in the blood is roughly two minutes before enzymes break it down. The window in which it can act is tiny. The breakthrough of GLP-1 receptor agonist medications is that they are engineered “long-acting” versions of that same signal — structurally modified to resist enzyme breakdown so the message lasts hours or even a full week. Semaglutide (Ozempic/Wegovy) is a once-weekly injection; tirzepatide (Mounjaro/Zepbound) is also once-weekly.

How do GLP-1 medications work? The 4 core mechanisms

The reason GLP-1 medications produce such meaningful weight loss is that they do not rely on a single pathway. They influence energy intake and metabolism on four fronts at once.

1. They extend the feeling of fullness

GLP-1 receptors sit in the hypothalamus — the brain’s central hub for regulating appetite and body weight. By keeping these receptors activated, the medication keeps the brain hearing “I’m full,” so hunger is slow to return even hours after eating. Many people describe the old “I have to eat right now” urgency simply fading — some even say they have to remind themselves to eat.

2. They slow stomach emptying

How quickly your stomach moves food into the small intestine (medically, the “gastric emptying rate”) strongly affects when you feel hungry again. GLP-1 medications slow this down, so the same meal stays in your stomach longer. The practical effect: fullness lasts longer, and the next wave of hunger arrives later. This is a major reason users naturally reduce how much they eat — without grinding through willpower.

3. They quiet the brain’s food cravings

GLP-1 receptors are not only in the hypothalamus; they also sit in the brain’s reward circuitry (areas like the nucleus accumbens). These regions don’t govern “am I hungry?” — they govern “do I want it?”, especially the pull toward high-fat, high-sugar food. One of the most consistent findings in both clinical studies and patient reports is that cravings for chips, sweets and takeout drop sharply. It is less “I want it but I’m resisting” and more “I just don’t want it as much.” That shift at the level of desire — rather than discipline — is a big part of why GLP-1 therapy is easier to sustain than dieting alone.

4. They improve blood-sugar control

GLP-1 was originally developed to treat type 2 diabetes, which explains its fourth mechanism. It prompts the pancreas to release insulin in a glucose-dependent way — meaning it only triggers insulin when blood sugar is elevated, so it does not cause low blood sugar when levels are normal. It also restrains excess glucagon release, helping keep blood sugar steadier. Stable blood sugar means fewer sharp dips that masquerade as “false hunger” and fewer physiological urges for sweets. Even in people without diabetes who are using it for weight loss, this works quietly in the background.

Semaglutide vs tirzepatide — the dual-target difference

If semaglutide is “one key,” tirzepatide is “two keys at once.” On top of activating the GLP-1 receptor, tirzepatide (Mounjaro/Zepbound) also activates the GIP receptor (glucose-dependent insulinotropic polypeptide). GIP is another gut hormone that helps regulate fat metabolism and satiety in its own right. The two work together, and the effects stack.

What the trial data shows

The numbers below are averages from the major clinical-trial programs, achieved with lifestyle support. They are not promises for any one person — individual results vary widely.

That gap is clinically meaningful — for someone weighing 100 kg, the difference between roughly 15 kg and 20+ kg is very real. But it does not mean “tirzepatide is automatically right for you.” The two medications differ in side-effect profiles, drug interactions and individual response. Choosing a dual-target drug is a decision to make with a physician, based on your health history and metabolic picture — not on a weight-loss number alone.

Who is a candidate for GLP-1 medications?

GLP-1 receptor agonists are prescription medications with defined eligibility criteria — they are not appropriate for everyone who wants to lose weight. The mainstream clinical framework used in Canada and across North America generally looks like this.

Typically eligible:

• BMI ≥ 30 (obesity), or
• BMI ≥ 27 with at least one weight-related health condition (such as type 2 diabetes, high blood pressure, sleep apnea or abnormal blood lipids)
• Where lifestyle changes (diet and exercise) alone have not been enough

Generally not suitable if you:

• Are pregnant or planning pregnancy in the near term
• Have a personal or family history of medullary thyroid cancer (an animal-study signal; human risk data is still being studied)
• Have a history of Multiple Endocrine Neoplasia type 2 (MEN2)
• Have a history of acute or chronic pancreatitis
• Are allergic to any component of the medication

In addition, certain medications — some diabetes drugs in particular — may need dose adjustment while on a GLP-1 to avoid low blood sugar. This is exactly why a complete medical evaluation before starting is a necessary step, not a formality. This article is general information, not medical advice.

Realistic expectations — it is not a miracle drug

The effect of GLP-1 medications is real and rigorously validated. But treating it as a “miracle drug” is where many people go wrong.

It does not replace lifestyle change. In every clinical trial, GLP-1 weight-loss numbers were achieved alongside lifestyle coaching. Take the medication but change nothing about how you eat or move, and the results shrink. The drug lowers appetite and craving — but you still need to use that window to build new eating habits.

Weight regain after stopping is common. Most discontinuation studies show that within a year of stopping, people regain roughly two-thirds of the weight they lost. The reason is biological: the medication controls a neuro-hormonal state, and when you stop, the body’s “set point” drifts back, appetite returns and metabolic rate resets toward where it was. This is not a willpower failure — it is physiology. It means GLP-1 is best viewed as a long-term management tool, much like long-term medication for blood pressure or cholesterol, rather than a short sprint. Whether you need to stay on it long-term is a decision to make with your physician.

Side effects are common early on. Nausea, vomiting and diarrhea are the most common initial reactions, usually strongest in the first few weeks and easing as the dose is titrated up slowly. Constipation can be a more persistent issue for some and needs active management (fibre and fluids). Starting low and going slow is the standard approach to keep side effects tolerable.

The facial side effect: “Ozempic face”

When you lose weight on a GLP-1 medication, the body sheds more than fat — facial subcutaneous fat and muscle volume can decline too, sometimes faster than elsewhere on the body. This is widely called “Ozempic face”: hollowed cheeks, deeper tear troughs, a softening jawline, and an overall look that can read several years older than the weight change alone would suggest.

This is not drug toxicity — it is a side effect of rapid weight loss itself. GLP-1 medications simply make weight loss faster, which makes the change more visible. The good news is that it can be anticipated and managed. Maintaining facial volume during weight loss — for example, with Sculptra (poly-L-lactic acid) to stimulate your own collagen, or hyaluronic acid dermal fillers to support facial contour — helps your face stay in proportion with your new body. For a full prevention plan, see our guide on Ozempic face: how to keep your face looking youthful while losing weight. At ID Cosmetic Clinic, where we primarily serve Asian faces, this kind of proportionate volume planning is something we discuss often.

The real takeaway

GLP-1 receptor agonists represent a genuine paradigm shift in weight-loss medicine — not a harsher diet and not simply “making you not want to eat,” but a recalibration of the body’s energy-regulation system across the brain, gut and pancreas at once. Precisely because the mechanism is sophisticated and the effect is strong, it deserves to be used under proper medical assessment and monitoring. Whether it suits you, which medication to choose, what dose to start at, how to pair it with lifestyle change and when to consider stopping — these are individualized questions, not things to copy from someone else’s experience.

Frequently asked questions

How does semaglutide work for weight loss?

Semaglutide mimics the natural gut hormone GLP-1. It extends fullness, slows stomach emptying, reduces food cravings in the brain’s reward centres, and helps steady blood sugar. Together these make you eat less naturally rather than by fighting hunger.

How fast do GLP-1 medications start working?

Most people notice stronger fullness and reduced appetite within 1–2 weeks. Visible weight change usually begins around 4–8 weeks, with results continuing to build over 12–16 weeks and beyond. The pace varies with dose, lifestyle and the individual.

Do I always regain the weight after stopping?

Most studies show people regain a large share of the weight within a year of stopping, because GLP-1 controls a neuro-hormonal state that resets when the drug stops. That is why GLP-1 is best used as a long-term management tool, with stopping decisions made together with your physician.

Can I use Ozempic for weight loss if I don’t have diabetes?

Yes. GLP-1 receptor agonists are approved for obesity in people without diabetes — generally BMI ≥ 30, or BMI ≥ 27 with a weight-related condition such as high blood pressure or sleep apnea. In Canada, Wegovy (higher-dose semaglutide) is the version designed for weight management. A physician must assess you and prescribe it.

What is the difference between GLP-1 medication and dieting?

Dieting relies on willpower to override appetite and is hard to sustain. GLP-1 medication adjusts the body’s fullness “set point” at the gut–brain level, making it easier and more natural to eat less. Both still need diet and exercise changes for the best and most lasting results.

What is the difference between semaglutide and tirzepatide?

Semaglutide activates the GLP-1 receptor. Tirzepatide activates GLP-1 and GIP receptors, and in trials produced greater average weight loss (~20–22% vs ~15%). Which is right for you depends on your health history, side-effect tolerance and physician judgment — not the weight number alone.

Do I need to exercise while on a GLP-1 medication?

Strongly recommended — especially strength training. GLP-1 weight loss can include muscle loss (roughly a quarter to 40% of total weight lost). Resistance training and adequate protein help preserve muscle, improve body composition and protect your metabolic rate.

What is “Ozempic face” and can it be prevented?

It is the hollowed, aged look that can follow rapid facial fat and volume loss during weight loss — not a drug toxicity. It can be anticipated and managed with collagen-stimulating treatments like Sculptra or hyaluronic acid fillers to maintain facial volume in proportion with your new weight.

Are GLP-1 medications safe?

For appropriate candidates under medical supervision, they have substantial safety and efficacy data. They are not suitable for everyone — including pregnancy, certain thyroid cancer or MEN2 history, and pancreatitis history. A full medical evaluation before starting is essential.

Related at ID Cosmetic Clinic

• Treatment: Physician-supervised medical weight loss
• Treatment: Sculptra collagen stimulation
• Treatment: Dermal fillers
• Condition: Ozempic face / facial volume loss
• Compare: Semaglutide vs tirzepatide
• Read next: Ozempic face: keeping your face youthful while losing weight